|Bid||2.4100 x 0|
|Ask||2.4200 x 0|
|Day's Range||2.4000 - 2.4800|
|52 Week Range||1.7200 - 10.2888|
|Beta (3Y Monthly)||1.72|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.05|
Financial highlights CHF 19.0 million cash & cash equivalents, trade and other receivables as at December 31, 2018Net operating costs decreased to CHF 14.3 million.
Kuros Biosciences (SIX:KURN) today announced that it has entered into a convertible bond financing agreement with Nice & Green S.A. for up to a maximum of CHF 5 million. The facility is provided by Nice & Green, a private Swiss company which specializes in financing solutions tailored to the requirements of listed growth companies in the biotech and cleantech industries. This agreement can be extended by Kuros for an additional CHF 5 million over a further period of 12 months.
Kuros Biosciences (SIX:KURN) today announced that its Dutch subsidiary, Kuros Biosciences BV, has received clearance for the Kuros TLIF cage from the U.S. Food and Drug Administration (FDA). The TLIF cage has been developed for the use with KUR-113, Kuros’s advanced Fibrin-PTH product candidate for spinal fusion. The Kuros TLIF cage is intended for use in intervertebral body fusion of the spine.
Kuros Biosciences (SIX:KURN) today announced that its Dutch subsidiary, Kuros Biosciences BV, has signed a private label Original Equipment Manufacturer (OEM) agreement with SeaSpine Holdings Corporation (SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders. Under the agreement Kuros will supply the bone graft in various forms and SeaSpine will market the products under the brand name OsteoCurrent in the U.S. and other select markets in Europe, South America and the Middle East providing the necessary regulatory approvals are achieved.
Kuros Biosciences (SIX:KURN) has completed a transformational year, having realized first sales of its MagnetOs bone graft substitute in the U.S. and Europe and raised capital to support the roll-out of MagnetOs, and fund the Phase II clinical trial of fibrin-PTH (KUR-113) in spinal fusion. Kuros raised gross proceeds of CHF 16.1 million from a capital increase on December 13, which will enable it to advance its pipeline, in particular the Phase II clinical study of its proprietary KUR-113 product in spinal fusion, and to progress commercialization of MagnetOs in the U.S. and selected geographies in Europe.
Kuros Biosciences (SIX:KURN) (the Company or Kuros) announces the final number of offered shares and gross proceeds from the rights offering and share placement, first announced on November 29, 2018, in which a total of 8,013,306 new registered shares of Kuros sourced from the ordinary and authorized share capital with a nominal value of CHF 1.00 each were offered at an offer price of CHF 2.50 per share.
Kuros Biosciences (SIX:KURN) (the Company or Kuros) announces the results of the rights offering, first announced on November 29, 2018, in which a total of 8,013,306 new registered shares of Kuros sourced from the ordinary and authorized share capital with a nominal value of CHF 1.00 each were offered to Kuros’ existing shareholders at an offer price of CHF 2.50 per share. At expiration of the rights exercise period on December 12, 2018, 12.00 noon CET, subscription rights for 2,769,608 new registered shares were validly exercised, representing 34.6% of the new registered shares offered.
Kuros Biosciences (SIX:KURN) today announced that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for extending MagnetOs Putty indications to use as a stand-alone bone graft in extremities and pelvis. This is in addition to the existing clearance for use of MagnetOs Granules and MagnetOs Putty as an autograft extender in posterolateral spine.
Kuros Biosciences (SIX:KURN) today announced the publication of data from a clinically-relevant preclinical model comparing MagnetOs with autologous bone in instrumented posterolateral spinal fusion in sheep. Utilizing multiple assessments for fusion, the study concluded that MagnetOs is a suitable alternative to autograft when used as a standalone graft.